Type 1 diabetes is increasing. Find the most up to date resources on screening, delaying, and managing.
Type 1 diabetes incidence and prevalence is increasing. Many studies indicate that measuring islet autoantibodies in relatives of those with type 1 diabetes can effectively identify those who will develop it. Testing, coupled with education about diabetes symptoms and close follow-up, has been shown to enable earlier diagnosis and to prevent diabetes ketoacidosis.
What should clinicians know about screening, treating, and complications around type 1 diabetes? Learn more below about how to optimize your care for people at risk or currently managing type 1.
The American Diabetes Association (ADA) convened leading experts—including endocrinologists, researchers, primary care professionals, certified diabetes care and education specialists, and mental health professionals—to discuss type 1 diabetes screening and awareness. These discussions culminated in the February 2025 report and the December 2023 report.
Participating associations
February 2025 Report December 2023 Report
The reports do not necessarily reflect official guidelines or recommendations from the ADA or other participating organizations.
*December 2023 Roundtable
^February 2025 Roundtable
The ADA states "It is important for health care professionals to realize that classification of diabetes type is not always straightforward at presentation and that misdiagnosis is common and can occur in ∼40% of adults with new type 1 diabetes."
Read the Standards of Care in Diabetes’ (Standards of Care’s) recommendations on type 1 diabetes screening and diagnosis.
In this special edition Diabetes Core Update podcast episode, Dr. Neil Skolnik and guest Dr. Jay Shubrook examine the evolving role of primary care in the early detection and delay of type 1 diabetes. They discuss current evidence supporting population-level autoantibody screening, risk stratification approaches, and emerging therapies aimed at preserving β-cell function.
Being screened for diabetes has a significant emotional and mental health toll. These resources offer support to patients and their families.
These documents provide at-a-glance guidance for type 1 diabetes screening based on the Standards of Care.
Earn free continuing education (CE) credit with courses, webinars, and more in the ADA’s Institute of Learning.
School nurses play an important role for students with type 1 diabetes and their caregivers. Training resources are available.
Sanofi supports phase 3 of ADA’s Therapeutic Inertia program. The main goal of phase 3 is to promote the measurable adoption of evidence-based practices, strategies, programs and tools that address key barriers associated with therapeutic inertia in diabetes care, leading to improved, timely treatment modification and improved overall glycemic control in adult patients with type 2 diabetes. Sanofi also supported the American Diabetes Association’s 100 Years of Insulin, a year-long campaign that focused on awareness, education and promoting activities that build community.
